Kylie Kavanagh to Hypoglycemic Agents
This is a "connection" page, showing publications Kylie Kavanagh has written about Hypoglycemic Agents.
Connection Strength
0.518
-
Kavanagh K, Brown KK, Berquist ML, Zhang L, Wagner JD. Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. Metabolism. 2010 Jun; 59(6):914-20.
Score: 0.331
-
Kavanagh K, Flynn DM, Nelson C, Zhang L, Wagner JD. Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey. J Pharmacol Toxicol Methods. 2011 May-Jun; 63(3):296-303.
Score: 0.089
-
Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, Harwood HJ. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther. 2010 Jun; 333(3):844-53.
Score: 0.083
-
Wagner JE, Kavanagh K, Ward GM, Auerbach BJ, Harwood HJ, Kaplan JR. Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J. 2006; 47(3):259-71.
Score: 0.016